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ABSTRACT The antimicrobial resistance (AMR) rates and levels recorded for Clostrid-
ium difﬁcile are on the rise. This study reports the nature, levels, diversity, and genomic
context of the antimicrobial resistance of human C. difﬁcile isolates of the NAPCR1/
RT012/ST54 genotype, which caused an outbreak in 2009 and is endemic in Costa
Rican hospitals. To this end, we determined the susceptibilities of 38 NAPCR1 isolates
to 10 antibiotics from seven classes using Etests or macrodilution tests and examined 31
NAPCR1 whole-genome sequences to identify single nucleotide polymorphisms (SNPs)
and genes that could explain the resistance phenotypes observed. The NAPCR1 isolates
were multidrug resistant (MDR) and commonly exhibited very high resistance levels. By
sequencing their genomes, we showed that they possessed resistance-associated SNPs
in gyrA and rpoB and carried eight to nine acquired antimicrobial resistance (AMR)
genes. Most of these genes were located on known or novel mobile genetic ele-
ments shared by isolates recovered at different hospitals and at different time
points. Metronidazole and vancomycin remain the ﬁrst-line treatment options for
these isolates. Overall, the NAPCR1 lineage showed an enhanced ability to acquire
AMR genes through lateral gene transfer. On the basis of this ﬁnding, we recom-
mend further vigilance and the adoption of improved control measures to limit the
dissemination of this lineage and the emergence of more C. difﬁcile MDR strains.
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Clostridium difﬁcile has attracted attention as an emerging pathogen on account ofthe worldwide spread of outbreak-causing strains (1), its changing epidemiology
(2), and the growing incidence, severity, and health care costs associated with C. difﬁcile
infections (CDI) (3). Indeed, some consider that CDI have surpassed methicillin-resistant
Staphylococcus aureus infections as the most common hospital-onset, health care
facility-associated infections (4).
Partly because of the rapid spread of successful clones, such as the ﬂuoroquinolone-
resistant NAP1 strains with mutations in gyrA (5), but also because of the rich array of
conjugative transposons (CTn), transposons (Tn), and mobilizable transposons (mobTn)
that characterize some strains of this species (6), the antimicrobial resistance (AMR)
rates and levels recorded for C. difﬁcile are increasing around the globe (7–9).
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This worrisome issue, along with the recognized role of several antibiotics in the
etiology of CDI (10) and the mobility of the gut resistome (11), justiﬁes continuous
monitoring of antimicrobial resistance in C. difﬁcile, its etiology, and the mechanisms
through which it spreads., To date, these issues have not been explored using whole-
genome sequencing in Latin American hospitals.
Along with the epidemic strain NAP1/RT027/ST01, a novel genotype of C. difﬁcile
termed NAPCR1/RT012/ST-54 (NAPCR1 variant with ribotype [RT] 012 and sequence type
[ST] 54) caused an outbreak of CDI in a major Costa Rican hospital in 2009 (12). NAPCR1
isolates induced a severe clinical presentation, were associated with mortality and
recurrence rates comparable to those of NAP1/RT027 strains, and produced a strong
inﬂammatory reaction in animal models (12). These strains continue to circulate in
several hospitals of this Central American country (13), and their closest known relative
is the multidrug-resistant (MDR) strain CD630, which is also classiﬁed as RT012/ST-54
and has been claimed to carry bona ﬁde determinants for tetracycline, erythromycin,
daunorubicin, bacitracin, nogalamycin, beta-lactam, tellurite, streptogramin, and lan-
tibiotic resistance (14).
We compared the susceptibilities to 10 antimicrobials of seven pulsed-ﬁeld gel electro-
phoresis (PFGE) subtypes of NAPCR1 isolates recovered from patients with diarrhea over
the past decade. This phenotypic analysis was followed by a detailed examination of
whole-genome sequences (WGS) in order to determine the etiology and genomic context
of the resistance phenotypes observed.
RESULTS
Antimicrobial susceptibility proﬁles. In Costa Rica, epidemiological surveillance of
C. difﬁcile is performed using pulsed-ﬁeld gel electrophoresis (PFGE). We analyzed 38
NAPCR1 isolates with 10 different PFGE SmaI patterns (Table 1) on account of their
epidemic potential, high virulence, and close relationship to CD630 (Fig. 1). Although
different resistance levels and patterns were seen across and within PFGE SmaI patterns
(Table 2), all these bacteria were resistant to 4 to 7 classes of antimicrobials and were
therefore categorized as MDR (Table 2). With a single exception, all isolates were
categorized as resistant to clindamycin, ciproﬂoxacin, levoﬂoxacin, moxiﬂoxacin, and
chloramphenicol. Moreover, resistance rates above 85% were recorded for tetracycline
(33 of 38 isolates [87%]) and rifampin (31 of 32 isolates [97%]), and 90% of the isolates
studied showed diminished susceptibility to linezolid (34/38 [92%]). In contrast, roughly
two-thirds of the isolates were susceptible to tigecycline (24/38 [63%]), 4 isolates
had diminished susceptibility to vancomycin (11%), and none of the isolates showed
resistance to metronidazole (Table 2). Across all isolates and their antimicrobial resis-
tance (AMR) proﬁles, no obvious patterns of increased resistance over time could be
seen in the data set.
Genotypic mapping of the observed phenotypic resistance proﬁles. Twenty-
nine sequenced NAPCR1 isolates with PFGE SmaI pattern 442, 447, 448, 449, 452, 487,
488, 558, or 578 had the gene encoding the ribosomal protection protein TetM carried
on Tn5397 and were, accordingly, tetracycline resistant (Table 3). On the other hand,
both NAPCR1 isolates with the SmaI macrorestriction pattern 489 studied lacked Tn5397
and were susceptible to tetracycline.
All NAPCR1 isolates carried a single copy of ermB, the product of which confers
resistance to clindamycin, inserted into the Tn5398 variant element that is characteristic
of C. difﬁcile 630Δerm (Table 3; Fig. 2).
All isolates sequenced showed a Thr82Ile substitution in the gyrA gene, encoding
DNA gyrase, as well as two rpoB mutations leading to the His502Asn and Arg505Lys
substitutions (Table 3). The Thr82Ile mutation correlated with ﬂuoroquinolone resis-
tance and the other two mutations did so with rifampicin resistance.
In addition, all NAPCR1 WGS include two copies of the chloramphenicol acetyltransferase-
carrying transposon Tn4453a inserted into homologues of the CD630_04230 and
CD630_18620 helicases of CTn2 and CTn5, respectively (Table 3; Fig. 3 and 4). Accord-
ingly, all NAPCR1 isolates are resistant to chloramphenicol.
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Other resistance genes and resistance-related mobile genetic elements (MGE).
Although all sequenced NAPCR1 isolates included a vanG-like cluster (data not shown),
only a few isolates showed decreased vancomycin susceptibility. This incongruence has
been reported previously (15).
A gene coding for a putative radical SAM protein marginally resembling the rRNA
dimethyltransferase Cfr was found, along with the aminoglycoside-streptothricin resis-
tance gene cluster ant6–sat4–aphA-3, in three variants of a Tn916-like element in both
linezolid-resistant and linezolid-susceptible NAPCR1 isolates (Table 3; Fig. 5). The largest
and most common variant of this MGE was shared by isolates with PFGE SmaI patterns
442, 447, 448, 449, 452, 488, 489, 558, and 578. It included two putative mobTn: one
with the cfr-like gene mentioned above and one with a gene showing partial matches
to the gene encoding the 16S rRNA methyltransferase KsgA and an adjacent sigma
factor (Fig. 5). The second variant was restricted to isolates with PFGE SmaI pattern 487
and lacked the mobTn with the ksgA-like gene (Fig. 5), which, instead, was found
inserted into a putative conjugative gene of CTn2 (CD630_04140) (Fig. 3). The third
variant did not have the mobTn with the cfr-like gene and was unique to the NAPCR1
isolate with PFGE SmaI pattern 447, LIBA-5701 (Fig. 5).
Except for isolates with PFGE SmaI pattern 487, the NAPCR1 WGS possessed two
copies of a putative mobTn element inserted into genes homologous to those encod-
TABLE 1 Clostridium difﬁcile NAPCR1 isolates included in the study
Isolate
PFGE SmaI pattern
(no. of isolates) Hospitala Yr(s) of isolation
LIBA-3147 442 (1) HSJD 2003
LIBA-2994 447 (6) HCG 2009
LIBA-5701 HSJD 2009
LIBA-5711 HSJD 2009
LIBA-5767 HCG 2009
LIBA-5771 CENARE 2009
LIBA-6281 HMX 2011–2012
LIBA-2784 448 (12) HBC 2003
LIBA-2954 HMX 2009
LIBA-2991 HCG 2010
LIBA-2993 HCG 2010
LIBA-3125 HSJD 2003
LIBA-3137 HSJD 2003
LIBA-5434 HBC 2003
LIBA-5704 HSJD 2009
LIBA-5707 HSJD 2009
LIBA-5751 HMX 2009
LIBA-5774 HMX 2009
LIBA-6275 HMX 2011–2012
LIBA-3129 449 (6) HSJD 2003
LIBA-5719 HSJD 2009
LIBA-5750 HMX 2009
LIBA-5755 HMX 2009
LIBA-5772 HSVP 2009
LIBA-6276 HMX 2011–2012
LIBA-5734 452 (1) HSJD 2009
LIBA-2945 487 (4) CENARE 2009
LIBA-5763 HCG 2009
LIBA-5769 HCG 2009
LIBA-5770 HCG 2009
LIBA-2992 488 (1) HCG 2009
LIBA-5761 489 (2) HEB 2009
LIBA-5762 HEB 2009
LIBA-3145 558 (2) HSJD 2003
LIBA-6285 HMX 2011–2012
LIBA-3144 578 (3) HSJD 2003
LIBA-3150 HSJD 2003
LIBA-5436 HBC 2003
aHSJD, San Juan de Dios Hospital; HCG, Calderón Guardia Hospital; CENARE, Centro Nacional de
Rehabilitación; HMX, México Hospital; HBC, Blanco Cervantes Hospital; HSVP, San Vicente de Paúl Hospital;
HEB, Enrique Baltodano Hospital.
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ing transcriptional regulators CD630_02920 and CD630_31200 (Table 3; Fig. 6). This
novel mobTn includes in its sequence a copy of the composite transposon Tn4001,
which encodes a bifunctional aminoglycoside-modifying enzyme (AME) with both
acetyltransferase and phosphotransferase functions (aacA-aphD) (Table 3; Fig. 6). The
NAPCR1-487 isolates carried another putative bifunctional aminoglycoside-modifying
enzyme, but in a phage-like sequence inserted into the CD630_18620 helicase of CTn5
(Fig. 4). The latter bifunctional aminoglycoside-modifying enzyme shows 56% identity
to orthologous proteins from Campylobacter jejuni and C. difﬁcile (NCBI protein acces-
sion numbers AGV79342.1 and WP_004452859.1) and is ﬂanked by a gene encoding a
protein with a GNAT acetyltransferase domain and a phosphotransferase from C. difﬁcile
(61% identity to NCBI protein accession number WP_021424056.1).
DISCUSSION
We have completed the ﬁrst genomic study of C. difﬁcile in Costa Rica to determine
the underlying diversity of AMR-associated single nucleotide polymorphisms (SNPs)
and genes of isolates causing disease. We showed that NAPCR1 isolates are noteworthy
not only because of the number of classes of antibiotics to which they are resistant but
also because of their high MICs, the numbers of resistance genes detected in their
genomes, and the association of these AMR-related genes with multiple transmissible
or potentially transmissible MGE, some of which are novel.
Tetracycline resistance in human-associated strains of C. difﬁcile is commonly ex-
plained by carriage of Tn5397 or Tn916-like elements that, in addition to tetM variants
(16), include ermB (17). In contrast C. difﬁcile strains of swine origin have been shown
to be strongly associated with tetW (18). In agreement with their human intestinal
origin, those sequenced isolates with phenotypically conﬁrmed tetracycline resistance
carried Tn5397.
The widespread clindamycin resistance of C. difﬁcile is often linked to the rRNA
adenine N-6-methyltransferase encoded by ermB. The best-known erm MGE in this
species is the nonconjugative mobTn Tn5398, which contains two ermB copies (19).
Laboratory strains positive for Tn5398 may become clindamycin susceptible through
the loss of one ermB copy, although reversion of the phenotype may also occur (20).
This might be the case for our sequenced isolates, since they naturally lost one ermB
copy but retained their phenotypic resistance to clindamycin.
FIG 1 Despite clustering with CD630 in a core SNP tree that includes representatives of all six C. difﬁcile MLST clades (left), the NAPCR1 isolates (highlighted in
blue) can be clearly distinguished from this MDR reference strain (right). SmaI patterns (PT), ribotypes (RT), and sequence types (ST) are given after isolate
designations when available. Bars represent the average numbers of substitutions per site.
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Mutations in the DNA gyrase GyrA or GyrB and in RNA polymerase subunit B (RpoB)
confer resistance to ﬂuoroquinolones and rifampin, respectively. Our NAPCR1 isolates
share the ﬂuoroquinolone resistance mutation Thr82Ile in GyrA, in addition to the RpoB
substitutions Arg505Lys and His502Asn, known to confer high levels of resistance to
rifampin on epidemic strains of C. difﬁcile (21). In this regard, it is tempting to speculate
that the Thr82Ile mutation in GyrA contributed to the epidemic potential shown by the
NAPCR1 strains when they caused an outbreak in 2009.
Although all strains possessed VanG-like sequences, most remained susceptible to
vancomycin. The genomic and experimental results at hand indicate that all NAPCR1
isolates share the same slpA allele, but in the future, we aim to address the cell wall
structure and antibiotic binding characteristics of these isolates in order to understand
the lack of congruence between genotypic and phenotypic data.
With regard to chloramphenicol resistance, this antibiotic is not widely used in
human medicine, although different phenicols are used in animal farming (F. García,
personal communication). It is not known at present whether animal- and farm-
associated isolates of C. difﬁcile from Costa Rica carry Tn4453 or cat genes in other
molecular contexts.
TABLE 2 Antibiotic susceptibility proﬁles of Clostridium difﬁcile NAPCR1 isolates
Isolate
SmaI
pattern
MIC (g/ml)a
Tetracy-
clines
Lincosamides
(CLI)
Quinolones
Nitroimidazoles
(MET)
Ansamycins
(RIF)
Glycopeptides
(VAN)
Oxazolidinones
(LIN)
Phenicols
(CHL)TET TIG CIP LEV MOX
LIBA-3147 442 0.38 0.064 >256 256 256 NAb 0.25 128 1 1 64
LIBA-2994 447 64 0.5 >256 128 >256 16 0.25 >32 1 8 >256
LIBA-5701 64 0.064 >256 >32 >32 >32 0.19 NAb 1 1 128
LIBA-5711 64 0.094 >256 >32 >32 >32 0.5 NA 2 1 128
LIBA-5767 64 0.125 >256 128 >256 16 0.25 256 1 6 >256
LIBA-5771 64 0.125 >256 128 >256 16 1 128 2 8 >256
LIBA-6281 64 0.125 >256 >32 >32 >32 0.25 >32 0.75 8 >256
LIBA-2784 448 64 0.125 8 >32 >32 >32 2 NA 1 8 >256
LIBA-2954 32 0.25 >256 128 >256 >32 0.5 128 4 8 >256
LIBA-2991 64 0.5 >256 128 >256 16 0.5 >32 1 8 >256
LIBA-2993 64 0.5 >256 128 >256 16 0.25 >32 0.125 8 >256
LIBA-3125 64 0.25 >256 256 256 >32 0.25 128 1 6 >256
LIBA-3137 64 0.125 8 256 256 >32 0.25 0.125 1 8 >256
LIBA-5434 32 0.19 >256 256 256 >32 0.25 128 2 6 64
LIBA-5704 32 0.064 >256 >32 >32 >32 0.125 NA 1 6 64
LIBA-5707 64 0.094 >256 >32 >32 >32 0.75 NA 2 6 128
LIBA-5751 64 0.25 >256 128 >256 16 0.25 128 1 8 >256
LIBA-5774 96 0.25 >256 128 >256 >32 0.5 128 4 8 >256
LIBA-6275 64 0.064 >256 >32 >32 >32 0.25 >32 1.5 6 128
LIBA-3129 449 32 0.125 >256 >256 >256 >32 0.25 128 2 8 >256
LIBA-5719 64 0.094 >256 >32 >32 >32 0.25 NA 4 6 128
LIBA-5750 64 0.5 >256 128 >256 16 0.5 128 1 8 >256
LIBA-5755 64 0.25 >256 128 >256 16 0.5 128 2 8 >256
LIBA-5772 64 0.125 >256 128 >256 16 0.5 128 1 8 >256
LIBA-6276 64 0.064 >256 >32 >32 >32 0.25 >32 0.75 8 64
LIBA-5734 452 0.25 0.064 >256 >32 >32 >32 0.25 NA 4 12 64
LIBA-2945 487 64 0.094 >256 >32 >32 >32 0.5 >32 3 8 128
LIBA-5763 64 0.5 >256 >256 >256 16 0.25 128 0.5 8 >256
LIBA-5769 128 0.5 >256 >256 >256 32 0.25 >32 2 2 >256
LIBA-5770 128 0.5 >256 >256 >256 16 0.25 >32 1 4 >256
LIBA-2992 488 64 0.5 >256 128 >256 16 0.5 >32 1 8 >256
LIBA-5761 489 0.5 0.094 >256 128 >256 16 0.25 128 1 6 128
LIBA-5762 0.25 0.125 >256 128 >256 16 0.25 128 1 6 >256
LIBA-3145 558 64 0.25 >256 >256 >256 >32 0.25 128 1 6 >256
LIBA-6285 1 0.064 >256 >32 >32 >32 0.25 >32 0.75 8 64
LIBA-3144 578 32 0.125 >256 >256 >256 >32 0.25 128 2 8 >256
LIBA-3150 32 0.047 >256 >256 >256 >32 0.25 128 1 8 128
LIBA-5436 32 0.19 >256 >256 >256 >32 0.25 16 2 12 >256
aTET, tetracycline; TIG, tigecycline; CLI, clindamycin; CIP, ciproﬂoxacin; LEV, levoﬂoxacin; MOX, moxiﬂoxacin; MET, metronidazole; RIF, rifampin; VAN, vancomycin; LIN,
linezolid; CHL, chloramphenicol. MIC values that indicate resistance or diminished susceptibility are shown in boldface. MICs were obtained with Etests or
macrodilution tests.
bNA, not assayed.
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The WGS of the isolates sequenced in this study, in addition to carrying genes
known to confer resistance to antimicrobials used in clinical therapy, also carried genes
conferring resistance to antimicrobials that are not used to treat C. difﬁcile but are
implicated in the development of CDI. This ﬁnding suggests either that lateral DNA
transfer in this lineage is very active and is independent of strong selective pressure
or that such resistance is maintained because it is coselected or offers other
selective advantages. This is not unexpected, considering that C. difﬁcile may be part
of the human gut microbiota. For instance, the rRNA methyltransferase encoded by cfr
modiﬁes the 23S rRNA and thereby provides protection against phenicols, lincos-
amides, pleuromutilins, streptogramin A antibiotics, and selected 16-membered
TABLE 3Mechanisms and molecular context of the antibiotic resistance of Clostridium difﬁcile NAPCR1 isolates from Costa Rican hospitals
SmaI pattern(s) (isolate) Resistance-associated SNPa Acquired resistance gene(s)
Molecular context of acquired
resistance
442, 448, 449, 452, 447,b
488, 558, 578
gyrA (Thr82Ile)
rpoB (His502Asn
Arg505Lys)
tetM Tn5397
ermB Tn5398 variant
aacA-aphD Tn4001 inserted into putative mobTn
catD Tn4453a inserted into CD630-CTn2
and CD630-CTn5
ant6–sat4–aphA-3–cfr-like gene Putative Tn916-like CTn-Ac
489 gyrA (Thr82Ile)
rpoB (His502Asn
Arg505Lys)
ermB Tn5398 variant
aacA-aphD Tn4001 inserted into putative mobTn
catD Tn4453a inserted into CD630-CTn2
and CD630-CTn5
ant6–sat4–aphA-3–cfr-like gene Putative Tn916-like CTn-Ac
487 gyrA (Thr82Ile)
rpoB (His502Asn
Arg505Lys)
tetM Tn5397
ermB Tn5398 variant
catD Tn4453a inserted into CD630-CTn2
and CD630-CTn5
Putative bifunctional aac-aph Phage-like element
ant6–sat4–aphA-3–cfr-like gene Putative Tn916-like CTn-Bc
447 (LIBA-5701) gyrA (Thr82Ile)
rpoB (His502Asn
Arg505Lys)
tetM Tn5397
ermB Tn5398 variant
aacA-aphD Tn4001 inserted into putative mobTn
catD Tn4453a inserted into CD630-CTn2
and CD630-CTn5
ant6–sat4–aphA-3 Putative Tn916-like CTn-Cc
aThe MDR strain C. difﬁcile 630 was used as a reference.
bData shown for SmaI pattern 447 here apply to all isolates with this pattern except isolate LIBA-5701.
cThree variants of a putative Tn916-like CTn carrying the ant6–sat4–aphA-3 cluster (designated CTn-A, CTn-B, and CTn-C) were seen among the NAPCR1 strains.
FIG 2 Relative to strain CD630 (top), the NAPCR1 isolates lost one copy of ermB and a gene coding for a hydrolase (purple) in Tn5398 (center). This variant is
characteristic of strain CD630Δerm (bottom). Arrows and arrowheads represent open reading frames. Black arrows represent ermB copies.
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macrolides (22). This gene has been found in Tn6218 in C. difﬁcile (23). However, our
NAPCR1 isolates, irrespective of their sensitivity to linezolid, carry a gene showing partial
matches to cfr as part of a new Tn916-like element.
Notwithstanding the fact that aminoglycosides are not active against anaerobic bacte-
ria, many NAPCR1 isolates have at least two copies of a bifunctional aminoglycoside-
modifying enzyme (AME) with Aac(6=) and Aph(2) activities. This gene has already been
seen in C. difﬁcile as part of a novel family of transposons termed Tn6218 (24). However,
we found two copies, each of which was inserted into an element that resembles a
mobTn and contains Tn4001. Tn4001 was originally reported in Staphylococcus aureus
but was later found in Enterococcus sp., Enterococcus faecalis, Enterococcus faecium, and
Staphylococcus epidermidis strains from human guts (25). We found indirect evidence of
FIG 3 (Top) Two different variants of the CTn2 of strain CD630 were seen among the NAPCR1 isolates. (Center) In isolates with PFGE SmaI pattern 487, a
mobilizable transposon with a putative 16S rRNA methyltransferase gene (ksgA) is inserted into CD630_04140 (yellow arrows and arrowheads). (Bottom) All of
the NAPCR1 isolates carry a second copy of Tn4453a (red arrows), and therefore of catD (black arrow), inserted into homologues of the CD630_04230 helicase.
mobC, DNA mobilization gene; repA, replication gene; ksgA, gene encoding rRNA methyltransferase; rec, recombinase gene.
FIG 4 (Top) Two variants of the CTn5 of strain CD630 were seen among the NAPCR1 isolates. (Center and bottom) All isolates have the catD gene (black
arrowhead) of Tn4453a (red arrows and arrowheads) inserted into homologues of the CD630_18620 helicase. In addition, isolates with PFGE SmaI pattern 487
have a phage-like sequence (blue arrows and arrowheads) disrupting the same helicase at another position (bottom). This phage-like element contains a cluster
of three putative aminoglycoside resistance genes (black arrowheads), one of which seems to encode a bifunctional Aac-Aph enzyme. abiH, phage abortive
infection gene; rec, recombinase gene; TMP, tail tape measure gene; MCP, major capsid; terL, terminase large-subunit gene; terS, terminase small-subunit gene;
pol, DNA polymerase gene; aac-aph, genes encoding a bifunctional aminoglycoside acetyltransferase/phosphotransferase.
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its mobility in C. difﬁcile. In a few NAPCR1 isolates, another allele for a bifunctional AME
was seen in a putative phage as part of a gene array including genes with matches to
other types of potential AMEs. This phage shows multiple features of the family
Siphoviridae and is more closely related to phage from Enterococcus spp. than to
cognates from Clostridium spp. (data not shown), suggesting that the NAPCR1 isolates
FIG 5 The NAPCR1 isolates have three variants of a composite Tn916-like element inserted into the putative group 1 glycosyltransferase CD630_08430 of strain
CD630 (top). All three variants include an ant6–sat4–aphA-3 aminoglycoside-streptothricin cluster (array of three black arrowheads). Two variants have a gene
coding for a radical SAM enzyme showing partial matches to cfr in a putative mobilizable transposon (single black arrow within blue arrows and arrowheads).
One of these also has the mobilizable transposon positive for the putative ksgA shown in Fig. 3 (yellow arrows and arrowheads), as does the variant without
the cfr-like gene. The mobilizable transposon containing the ksgA-like gene is inserted into CTn2 in isolates with the PFGE SmaI 487 pattern. int, gene encoding
integrase; xis, gene encoding excisionase; rec, gene encoding recombinase; mobC, DNA mobilization gene; CP, conjugative gene; repA, replication gene; ksgA,
gene encoding rRNA methyltransferase; ardA, antirestriction gene; ftsK-spoIIIE, DNA transporter gene.
FIG 6 Except for isolates with PFGE SmaI pattern 487, the NAPCR1 isolates have two copies of an uncharacterized MGE, each of which is inserted into a
homologous gene of the putative transcriptional regulator CD630_02920 (top) or CD630_31200 (bottom). Along with other functions (orange arrows), this
putative MGE includes a bifunctional aacA-aphD gene (black arrows) within Tn4001 (blue arrows). repA, replication gene; tnp, transposase-encoding gene; rec,
recombinase-encoding gene.
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actively exchange DNA with other intestinal Firmicutes. Although it has been shown
that C. difﬁcile phage can mediate the transduction of MGE containing AMR genes (26),
if the NAPCR1 phage and its AME are indeed functional, this is the ﬁrst report of a C.
difﬁcile phage with AMR genes.
The NAPCR1 isolates also have the aminoglycoside-streptothricin resistance gene
cluster ant6–sat4–aphA-3, which characterizes staphylococci, Campylobacter coli, and E.
faecium strains of different origins (27). In most staphylococci, the ant6–sat4–aphA-3
array is integrated into Tn5405 (27). However, our isolates have this array inserted into
a putative Tn916-like CTn related to CD630-CTn1. The chimeric nature of this composite
element strongly suggests that its mobTn are functional.
In addition to these AMR genes, all of the NAPCR1 isolates carry three genes
previously annotated in strain CD630 (14) as encoding a beta-lactamase (CD0458), a
beta-lactamase regulatory protein (CD0470), and a beta-lactamase repressor (CD0471)
(data not shown). Although these antibiotics are not regularly used to treat CDI, some
of them clearly seem to lead to CDI (1).
In parallel to the NAPCR1 isolates, we performed this survey on one NAP2 strain, one
NAP4 strain, one NAP6 strain, and ﬁve NAP1 strains that cocirculated in time and space.
A principal-component analysis on this extended susceptibility data set clearly distin-
guished the proﬁles of NAPCR1 strains from those of the other genotypes (data not
shown), highlighting the fact that the NAPCR1 strains are different. In agreement with
this result, these non-NAPCR1 isolates lacked the MGE that characterized the NAPCR1
strains.
In summary, a phenotypic and genomic survey revealed that during the past
decade, MDR was widespread among NAPCR1 isolates from various Costa Rican hospi-
tals. This trait was due to a variety of resistance mechanisms, some of which are absent
in the closely related MDR strain CD630 and also in cocirculating strains. Our results
highlight the usefulness of comparative genomics in the epidemiological surveillance
of antibiotic resistance, point to the need for further monitoring of circulating strains
for early detection of metronidazole and vancomycin resistance, and justify further
development of antibiotic-independent treatments for CDI.
MATERIALS AND METHODS
Strains and C. difﬁcile isolation. A total of 38 NAPCR1 C. difﬁcile isolates recovered from seven Costa
Rican hospitals between 2003 and 2010 were studied (Table 1). These bacteria were taken from a
collection maintained at the Anaerobic Bacteriology Research Laboratory of the University of Costa Rica.
Without exception, they were derived from stool samples positive for C. difﬁcile toxins as revealed by
rapid immunochromatographic assays. For isolation, ethanol-treated samples were inoculated onto
cefoxitin-cycloserine-fructose agar (CCFA; Oxoid) plates that were incubated under anaerobic conditions
(90% N2, 5% H2, and 5% CO2) in a Bactron II chamber. To conﬁrm their identiﬁcation, we used the Rapid
ID 32A system (bioMérieux) based on preformed enzymes, a PCR targeting tpi (28), and, in some cases,
determination of fatty acid methyl ester proﬁles through gas chromatography (MIDI, microbial identiﬁ-
cation system).
PFGE typing. The PFGE procedure followed was derived from a published protocol (12). Brieﬂy,
agarose plugs were prepared by mixing equal volumes of bacteria from 6- to 8-h cultures and SeaKem
Gold agarose (Lonza) in 1 Tris-EDTA buffer containing SDS (Sigma). These plugs were then incubated
in a buffer composed of lysozyme, RNase A, and mutanolysin (Sigma). After overnight digestion with
SmaI (Roche), DNA fragments were separated on 1% agarose gels (Bio-Rad) prepared with 0.5 Tris
borate-EDTA buffer and 50 M thiourea (Sigma) using a CHEF-DR II system (Bio-Rad). Digitized images
were analyzed with BioNumerics software (version 6.0; Applied Maths), and the resulting macrorestriction
patterns were compared with those deposited in the databases of the National Microbiology Laboratory
(Public Health Agency of Canada).
Antimicrobial susceptibility testing. The MICs of tetracycline (resistance breakpoint, 16 mg/liter),
tigecycline (0.25 mg/liter), clindamycin (8 mg/liter), cefotaxime (64 mg/liter), ciproﬂoxacin (8
mg/liter), levoﬂoxacin (8 mg/liter), moxiﬂoxacin (8 mg/liter), metronidazole (32 mg/liter), rifampin
(0.004 mg/liter), chloramphenicol (32 mg/liter), vancomycin, and linezolid were determined using
Etests (bioMérieux) or macrodilution tests. These assays were repeated 2 to 3 times using independent
cultures. Resistance breakpoints were set in compliance with Clinical and Laboratory Standards Institute
guidelines (29) or EUCAST epidemiological cutoff values (30), when available. For vancomycin and
linezolid, we categorized MICs between 4 and 8 mg/liter as indicating reduced susceptibility (31). Isolates
for which linezolid MICs were 8 mg/liter were categorized as resistant. For ciproﬂoxacin, we used the
breakpoint deﬁned for other ﬂuoroquinolones. According to standardized international terminology (32),
MDR was deﬁned as acquired nonsusceptibility to at least one agent in each of three or more
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antimicrobial classes. The panel of antibiotics tested included drugs used in the treatment of CDI
(tigecycline), the development of CDI (expanded-spectrum ﬂuoroquinolones), front-line treatments
(metronidazole, vancomycin), and alternative treatments for CDI (linezolid) and CDI relapses (rifampin).
Whole-genome sequencing and genomic analyses. WGS for 31 isolates were obtained by se-
quencing by synthesis using multiplexed paired-end libraries (see Table S1 in the supplemental material).
Reads were ﬁrst assembled into contigs using Velvet (33) or Edena (34) and were then mapped back to
assembly contigs to check for misassemblies. Single nucleotide polymorphisms (SNPs) were identiﬁed
using Burrows-Wheeler alignment (BWA) (35), SAMtools (36), BCFtools (37), and the genome of the MDR
reference strain CD630 (NCBI nucleotide accession number AM180355.1). For automated annotation, we
used Prokka, version 1.11 (38), and proprietary databases containing publicly available C. difﬁcile
genomes from reference strains. If required, annotations were reﬁned manually using BLAST, BLASTP,
PSI-BLAST, BYPASS, PRODOM, SMART, and UniProt searches. Contig ﬁles were scanned against C. difﬁcile
PubMLST typing schemes using multilocus sequence typing (MLST) (39). AMR genes were identiﬁed
manually, with ABRICATE and SRST2 (40), or through BLAST/BLAT searches against the CARD (41), ARDB
(42), and ARG-ANNOT (43) databases. Putative lateral gene transfer events were predicted using Alien
Hunter (44), PhiSpy (45), or ICEberg (46) and were veriﬁed though visual inspection of contigs ordered
with Mauve (47). Core genome SNP phylogenies were done with Parsnp (48) using the genomes of the
following strains: CD630 (NCBI nucleotide accession number AM180355.1), 2007855 (FN665654.1),
LIBA-5703 (EBI-ENA accession number ERR467551), LIBA-5710 (ERR467558), R20291 (NCBI nucleotide
accession number FN545816.1), CD196 (FN538970.1), BI1 (FN668941.1), OX1485 (EBI-ENA accession
number ERR232375), Ox2183 (ERR126286), M68 (NCBI nucleotide accession number FN668375.1), CF5
(FN665652.1), M120 (FN665653.1), CD10-165 (JRHN00000000.1), and SA10-050 (JRHM00000000.1). All
genomes and genome comparisons were visualized in Artemis (49) or ACT (50). Linear comparison
ﬁgures of multiple genomic loci were prepared with Easyﬁg (51).
Accession number(s). Sequencing data may be downloaded from the European Nucleotide Archive
(study PRJEB5034). The corresponding EBI-ENA accession numbers are ERR467530, ERR467534,
ERR467536, ERR467538, ERR467539, ERR467541 to ERR467547, ERR467550, ERR467552, ERR467555,
ERR467559, ERR467565, ERR467569, ERR467578, ERR467581, ERR467586 to ERR467588, ERR467592,
ERR467594 to ERR467596, ERR467601, ERR467602, ERR467607, and ERR467610 (Table S1).
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